Core Viewpoint - Clover Biopharmaceuticals-B (02197) experienced a significant increase in stock price, rising by 5.67% to HKD 2.98, with a trading volume of HKD 1.3738 million, following the announcement of positive preliminary data from two ongoing clinical trials [1] Group 1: Clinical Trials - The company announced positive preliminary data from two Phase I clinical trials [1] - One trial is being conducted in Australia to evaluate the respiratory combination vaccine candidates SCB-1022 and SCB-1033 against SCB-1019, targeting elderly individuals who have not previously received any RSV vaccine [1] - The second trial is taking place in the United States, assessing the head-to-head comparison of SCB-1019 with AREXVY in elderly individuals who had received at least two seasonal doses of AREXVY prior to enrollment [1] Group 2: Future Plans - Based on the positive results from the Phase I clinical trials, Clover Biopharmaceuticals plans to advance SCB-1022 and SCB-1033 to Phase II clinical trials in the first half of 2026 [1]
三叶草生物-B高开逾5% 两项临床试验获得积极初步数据